Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)—Analysis of Data from Daily Practice

Pantazis, Nikos; Pechlivanidou, Evmorfia; Antoniadou, Anastasia; Akinosoglou, Karolina; Kalomenidis, Ioannis; Poulakou, Garyfallia; Milionis, Haralampos; Panagopoulos, Periklis; Marangos, Markos; Katsarolis, Ioannis; Kazakou, Paraskevi; Dimakopoulou, Vasiliki; Chaliasou, Anna-Louiza; Rapti, Vasiliki; Christaki, Eirini; Liontos, Angelos; Petrakis, Vasileios; Schinas, Georgios; Biros, Dimitrios; Rimpa, Maria-Christina; Touloumi, Giota

doi:10.3390/microorganisms11081998

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of renal biopsy results from SARS-CoV-2 infected patients with and without underlying kidney disease revealed the prevalence of AKI in patients without preexisting kidney conditions, while those with such conditions were predisposed to CKD, primarily of the IgA nephropathy (IgAN) type [ 42 ]. While kidney disease and other adverse reactions post-COVID-19 vaccination appear to be rare overall, some studies suggest a potential link between COVID-19 vaccination and subsequent kidney disease [ 43–45 ]. According to Li Yebei et al.…”

Section: Discussionmentioning

confidence: 99%

Research on the global trends of COVID-19 associated acute kidney injury: a bibliometric analysis

Zhao,

Tan,

Gao

et al. 2024

Renal Failure

View full text Add to dashboard Cite

Critically ill COVID-19 patients may exhibit various clinical symptoms of renal dysfunction including severe Acute Kidney Injury (AKI). Currently, there is a lack of bibliometric analyses on COVID-19-related AKI. The aim of this study is to provide an overview of the current research status and hot topics regarding COVID-19 AKI. The literature was retrieved from the Web of Science Core Collection (WoSCC) database. Subsequently, we utilized Microsoft Excel, VOSviewer, Citespace, and Pajek software to revealed the current research status, emerging topics, and developmental trends pertaining to COVID-19 AKI. This study encompassed a total of 1507 studies on COVID-19 AKI. The United States, China, and Italy emerged as the leading three countries in terms of publication numbers, contributing 498 (33.05%), 229 (15.20%), and 140 (9.29%) studies, respectively. The three most active and influential institutions include Huazhong University of Science and Technology, Wuhan University and Harvard Medical School. Ronco C from Italy, holds the record for the highest number of publications, with a total of 15 papers authored. Cheng YC’s work from China has garnered the highest number of citations, totaling 470 citations. The co-occurrence analysis of author keywords reveals that ‘mortality’, ‘intensive care units’, ‘chronic kidney disease’, ‘nephrology’, ‘renal transplantation’, ‘acute respiratory distress syndrome’, and ‘risk factors’ emerge as the primary areas of focus within the realm of COVID-19 AKI. In summary, this study analyzes the research trends in the field of COVID-19 AKI, providing a reference for further exploration and research on COVID-19 AKI mechanisms and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Research on the global trends of COVID-19 associated acute kidney injury: a bibliometric analysis

Zhao,

Tan,

Gao

et al. 2024

Renal Failure

View full text Add to dashboard Cite

show abstract

Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan

Yoshida,

Taguchi,

Piao

et al. 2024

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Shevchuk,

Kryukov,

Temirbulatov

et al. 2023

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim of the work was to study the influence of clinical, demographic and pharmacogenetic factors on the development of drug-induced liver damage during remdesivir therapy in COVID-19 patients.Materials and methods. The study comprised 100 hospitalized patients treated with remdesivir. The patients were divided into two groups: group 1 (n=32) – remdesivir therapy, developed an increase in the level of liver transaminases; group 2 (control, n=68) – did not develop this adverse reaction. The patients in both groups underwent a pharmacogenetic study, and a retrospective analysis of medical records was performed. Based on the data obtained, the association of clinical, laboratory, pharmacological and pharmacogenetic parameters with the development of drug-induced liver damage during remdesivir therapy was studied.Results. In the group of patients with the development of drug-induced liver damage, people with a high body mass index were significantly more likely than in the control group (30.7±4.2 kg/m2 in group 1 vs. 27.3±5.5 kg/m2 in group 2, p=0.003), with a history of diabetes mellitus (odds ratio (OR)=2.647, 95% confidence interval (CI)=1.092–6.414, χ2=4.785, p=0.029), with higher levels of ferritin in the blood (724.03±432.27 and 553.19±358.48 mg/mol, respectively, p=0.040), receiving therapy with angiotensin-converting enzyme inhibitors (OR=5.440, 95% CI=2.160–13.699, χ2=14.027, p=0.000), statins (OR=3.148, 95% CI=1.307–7.581, χ2=6.795, p=0.009), and also being heterozygous for the polymorphic marker rs776746 of the CYP3A5 gene (OR=3.961, 95% CI=1.343–11.686, χ2=6.772, p=0.009).Conclusion. A high body mass index, a history of diabetes mellitus, high levels of ferritin in the blood, concomitant therapy with angiotensin-converting enzyme inhibitors and statins, as well as a carriage of the AG genotype for the polymorphic marker rs776746 of the CYP3A5 gene increase the likelihood of developing drug-induced liver damage during remdesivir therapy. In this regard, it is necessary to consider these factors when prescribing remdesivir therapy, conduct a more careful monitoring of clinical and laboratory indicators of liver damage, and develop personalized approaches to the treatment of COVID-19 patients.

show abstract

Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)—Analysis of Data from Daily Practice

Cited by 3 publications

References 35 publications

Research on the global trends of COVID-19 associated acute kidney injury: a bibliometric analysis

Research on the global trends of COVID-19 associated acute kidney injury: a bibliometric analysis

Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Contact Info

Product

Resources

About